SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Neurocrine Biosciences (NBIX) -- Ignore unavailable to you. Want to Upgrade?

To: DewDiligence_on_SI who wrote (1388)2/26/2005 12:35:03 PM
From: tom pope  Respond to of 1834
 
Silly nitpicking.



To: DewDiligence_on_SI who wrote (1388)2/26/2005 2:37:34 PM
From: Biomaven  Read Replies (1) | Respond to of 1834
 
Yes, that "rest of world" was wrong. Should have been "remainder of the ICOS Lilly marketing area."

But doesn't change the broader point that ICOS is going to have sharply rising direct sales cost, both within the US and outside it. (Stock is probably still cheap, though).

Peter


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News